Abstract
Activated glial cells are capable of generating various inflammatory mediators, including cytokines, nitric oxide and reactive oxygen species. These potentially neurotoxic molecules have been suggested to play a role in the etiology and development of depression. Accumulating evidence indicates that antidepressants have inhibitory effects on inflammatory activation of glial cells and confer neuroprotection under neuropathological conditions. Such efficacy of antidepressants appears to depend on suppressing microglial production of inflammatory substances and up-regulating both astrocytic secretion of neurotrophins and astrocytic glutamine synthase, which converts neurotoxic glutamate into non-toxic glutamine. Therefore, glial cells, both as source and target of inflammatory molecules, may represent a potential promising target involved in the pathophysiology of depression. Moreover, antidepressants have the possibility to be useful treatment, not only for depression, but for a broad spectrum of neuroinflammatory and neurodegenerative disorders where the pathogenesis is associated with glial activation.
Keywords: Antidepressants, anti-inflammatory effect, astrocyte; cytokine, depression, microglia, nitric oxide, reactive oxygen species.
Current Drug Targets
Title:Glia: An Important Target for Anti-Inflammatory and Antidepressant Activity
Volume: 14 Issue: 11
Author(s): Sadayuki Hashioka, Tsuyoshi Miyaoka, Rei Wake, Motohide Furuya and Jun Horiguchi
Affiliation:
Keywords: Antidepressants, anti-inflammatory effect, astrocyte; cytokine, depression, microglia, nitric oxide, reactive oxygen species.
Abstract: Activated glial cells are capable of generating various inflammatory mediators, including cytokines, nitric oxide and reactive oxygen species. These potentially neurotoxic molecules have been suggested to play a role in the etiology and development of depression. Accumulating evidence indicates that antidepressants have inhibitory effects on inflammatory activation of glial cells and confer neuroprotection under neuropathological conditions. Such efficacy of antidepressants appears to depend on suppressing microglial production of inflammatory substances and up-regulating both astrocytic secretion of neurotrophins and astrocytic glutamine synthase, which converts neurotoxic glutamate into non-toxic glutamine. Therefore, glial cells, both as source and target of inflammatory molecules, may represent a potential promising target involved in the pathophysiology of depression. Moreover, antidepressants have the possibility to be useful treatment, not only for depression, but for a broad spectrum of neuroinflammatory and neurodegenerative disorders where the pathogenesis is associated with glial activation.
Export Options
About this article
Cite this article as:
Hashioka Sadayuki, Miyaoka Tsuyoshi, Wake Rei, Furuya Motohide and Horiguchi Jun, Glia: An Important Target for Anti-Inflammatory and Antidepressant Activity, Current Drug Targets 2013; 14 (11) . https://dx.doi.org/10.2174/13894501113146660214
DOI https://dx.doi.org/10.2174/13894501113146660214 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Strategies of Engineering Nanoparticles for Treating Neurodegenerative Disorders
Current Drug Metabolism PERK-opathies: An Endoplasmic Reticulum Stress Mechanism Underlying Neurodegeneration
Current Alzheimer Research Pituitary Adenylate Cyclase Activating Polypeptide in Animal Models of Neurodegenerative Disorders - Implications for Huntington and Parkinsons Diseases
Letters in Drug Design & Discovery Small Molecules Activating TrkB Receptor for Treating a Variety of CNS Disorders
CNS & Neurological Disorders - Drug Targets Inflammatory Risk Factors and Pathologies Associated with Alzheimers Disease
Current Alzheimer Research Early Expression of Neuronal Dopaminergic Markers in a Parkinson’s Disease Model in Rats Implanted with Enteric Stem Cells (ENSCs)
CNS & Neurological Disorders - Drug Targets Activities of Venom Proteins and Peptides with Possible Therapeutic Applications from Bees and WASPS
Protein & Peptide Letters Prevention of Cardiovascular Diseases with Anti-Inflammatory and Anti- Oxidant Nutraceuticals and Herbal Products: An Overview of Pre-Clinical and Clinical Studies
Recent Patents on Inflammation & Allergy Drug Discovery Future Treatment for COPD: Targeting Oxidative Stress and its Related Signal
Recent Patents on Inflammation & Allergy Drug Discovery Indole Alkaloids and Semisynthetic Indole Derivatives as Multifunctional Scaffolds Aiming the Inhibition of Enzymes Related to Neurodegenerative Diseases – A Focus on Psychotria L. Genus
Current Topics in Medicinal Chemistry Mechanisms of Melatonin in Alleviating Alzheimer’s Disease
Current Neuropharmacology Subject Index To Volume 9
Current Medicinal Chemistry Antioxidants as a Preventive Treatment for Epileptic Process: A Review of the Current Status
Current Neuropharmacology Cell Cycle Regulatory Protein 5 (Cdk5) is a Novel Downstream Target of ERK in Carboplatin Induced Death of Breast Cancer Cells (Supplementary Data)
Current Cancer Drug Targets VDAC1 as a Player in Mitochondria-Mediated Apoptosis and Target for Modulating Apoptosis
Current Medicinal Chemistry Translating Induced Pluripotent Stem Cells from Bench to Bedside: Application to Retinal Diseases
Current Gene Therapy BCL-2 Family Proteins: The Mitochondrial Apoptotic Key Regulators
Current Cancer Therapy Reviews Amyotrophic Lateral Sclerosis and Oxidative Stress: A Double-Blind Therapeutic Trial After Curcumin Supplementation
CNS & Neurological Disorders - Drug Targets Mitogenomics: Recognizing the Significance of Mitochondrial Genomic Variation for Personalized Medicine
Current Pharmacogenomics and Personalized Medicine Expression and Function of the Endocannabinoid System in Glial Cells
Current Pharmaceutical Design